Modified LR-5 criteria based on gadoxetic acid can improve the sensitivity in the diagnosis of hepatocellular carcinoma

Table 2 Liver Imaging Reporting and Data System features consistency of assessment among different radiologists, n (%)

LI-RADS features	Reader 1	Reader 2	Reader 3	Reader 1 vs reader 2, k value (95%CI)	Reader 1 vs reader 3, k value (95%CI)	Reader 2 vs reader 3, k value (95%CI)	Kendall's W
Nonrim APHE	204 (83.6)	174 (71.4)	203 (83.3)	0.67 (0.35-0.65)	0.81 (0.39-0.76)	0.73 (0.15-0.54)	0.81
Nonperipheral washout	163 (67.8)	155 (63.5)	150 (61.5)	0.83 (0.77-0.94)	0.87 (0.78-0.96)	0.77 (0.66-0.87)	0.79
Enhancing capsule	116 (47.5)	105 (43.0)	120 (49.2)	0.47 (0.33-0.66)	0.37 (0.31-0.51)	0.23 (0.11-0.27)	0.52
Threshold growth	7 (2.9)	5 (2.0)	6 (2.5)	1	1	1	1
Mosaic architecture	106 (43.4)	108 (44.3)	125 (51.3)	0.86 (0.83-0.97)	0.85 (0.71-0.94)	0.69 (0.67-0.83)	0.89
Non-enhancing capsule	21 (8.6)	21 (8.6)	21 (8.6)	0.71 (0.42-0.98)	0.71 (0.42-0.98)	0.71 (0.42-0.98)	0.79
Blood products in mass	100 (41.0)	82 (33.6)	76 (31.1)	0.87 (0.73-0.91)	0.89 (0.87-0.99)	0.90 (0.86-0.97)	0.93
Fat in mass-more than adjacent liver	82 (33.6)	86 (35.2)	90 (36.9)	0.83 (0.71-0.94)	0.81 (0.73-0.93)	0.73 (0.61-0.86)	0.83
Nodule-in-nodule architecture	83 (34.0)	78 (32.0)	72 (29.5)	0.71 (0.61-0.79)	0.67 (0.59-0.71)	0.59 (0.52-0.63)	0.65
Corona enhancement	42 (17.2)	56 (23.0)	53 (21.7)	0.81 (0.71-0.89)	0.83 (0.71-0.95)	0.78 (0.65-0.91)	0.83
Restricted diffusion	211 (86.5)	217 (88.9)	207 (84.8)	0.81 (0.65-0.91)	0.77 (0.61-0.89)	0.80 (0.66-0.95)	0.85
Mild-moderate T2 hyperintensity	213 (87.3)	200 (82.0)	202 (82.8)	0.75 (0.61-0.97)	0.71 (0.60-0.97)	0.73 (0.15-0.73)	0.81
Fat sparing in solid mass	15 (6.1)	29 (11.9)	31 (12.7)	0.61 (0.41-0.82)	0.64 (0.41-0.86)	0.45 (0.21-0.68)	0.71
Iron sparing in solid mass	44 (18.0)	38 (15.6)	40 (16.4)	0.31 (0.11-0.47)	0.33 (0.17-0.52)	0.37 (0.19-0.61)	0.55
Transitional phase hypointensity	229 (93.9)	225 (92.2)	230 (94.3)	0.73 (0.51-0.90)	0.71 (0.61-0.83)	0.70 (0.51-0.83)	0.87
Hepatobiliary phase hypointensity	223 (91.4)	225 (92.2)	225 (92.2)	0.81 (0.78-0.95)	0.82 (0.77-0.95)	0.87 (0.53-0.92)	0.89
Subthreshold growth	18 (7.4)	19 (7.8)	19 (7.8)	0.84 (0.67-1.01)	0.89 (0.74-1.04)	0.84 (0.67-1.01)	0.91

LI-RADS: Liver Imaging Reporting and Data System; CI: Confidence interval; APHE: Arterial phase hyperenhancement.